Ranbaxy Laboratories Limited
NSE Symbol RANBAXY
RESULTS FOR CALENDAR YEAR
2010 vs 2009 & 2008
RANBAXY Laboratories has declared good results for Calendar Year 2010. These are compared below with the Calendar years 2009 and 2008 below :
Net Sales is Rs.5251.49 cr – on stand alone (SA) BASIS – Up by 16.15% from CY 2009 and up by21.89 from CY 2008. The same on consolidated (CS) basis is Rs.8535.45 cr –up by 16.45% from CY 2009 and up by 17.87% from CY 2008. Thus, sales has registered healthy increase in each year.
Total Expenditure on Stand alone (SA) basis is Rs.4526.88 cr – up by 14.38% from CY 2009 but down by 26.45% from CY 2008. The same on CS basis is Rs.7352.91 cr – up by 7.98% from CY 2009 and down by 18.18% from CY 2008. Expenditure is under reasonable control.
Profit from Operations on Stand Alone Basis is Rs.1145.22 Cr – against Rs.825 cr in CY 2009 and against LOSS of Rs.1683 Cr in CY 2008. The OPT on CS basis is Rs.1607.86 cr – against a profit of Rs.787.26 cr in CY 2009 and against a LOSS of Rs.1565.15 cr in CY 2008. Thus, there is healthy increase in Operational Profit with respect to the 2 previous years. In CY 2008 – there was a HUGE INCREASE IN OTHER EXPENDITURE – resulting in LOSS in that year even at operational level.
There is a big Exceptional items Minus Expdr / receipt of Rs.254.59 cr on SA basis and Rs.495.77 Cr on CS basis in CY 2010, which has boosted the profits further in CY 2010.
Profit before tax is therefore at Rs.1565.25 cr – up by 47.4% from CY 2009 and up by 196.67% from CY 2008 (which had a huge loss). The same on CS basis is Rs.2321.72 cr – up by 129.93% from CY 2009 and up by 254.78% from CY 2008 (which had a huge loss).
Net Profit is Rs.1148.73 cr in CY 2010 – up from Rs. 571.98 Cr of CY 2009 by 100.83% and by 209.95% from CY 2008 (which had a loss of Rs.1044.80 cr).
The NPT on CS basis is Rs.1736.85 basis – up by a huge 459.06% from Rs. 310.68 of CY 2009 and by 285.77% from CY 2008 (which had a huge loss of Rs. 934.95 cr)
Consolidated Net Profit is Rs.1496.75 cr against Rs.296.49 cr in CY 2009 (up by 404.82%) and against Rs.(-)951.21 cr in CY 2008 (up by 257.35%).
Against a Face value of Rs.5, the Basic EPS is Rs.27.3 in 2010; Rs.13.61 in CY 2009; and Rs.(-)27.29 in CY 2008 on SA basis.
The same on CS Basis is Rs.35.57 in CY 2010; Rs.7.05 in CY 2009; and Rs.(-)24.85 in CY 2008.
Thus, the current year results on all parameters are much better compared to the two preceding years.
RESULTS TABLE :
| CY 2010 SA | ||||||
| Net Sales | 525148.6 | 452118 | 430836.2 | 853545 | 732940.3 | 724140.7 |
| Net Sales | 525148.6 | 16.15 | 21.89 | 853545 | 16.45 | 17.87 |
| Other Oprtg Income | 42061.6 | 26158 | 16378.5 | 42532.1 | 26763.3 | 17994.8 |
| Incr./Dec. in SIT / WIP | -16142.5 | -3525.7 | -11558.9 | -31373.8 | 10973.8 | -17460.4 |
| Raw Materials | 168030.7 | 160207.9 | 157368.3 | 218452.3 | 239624.9 | 215657 |
| Traded goods | 65205.2 | 48120.6 | 42116.4 | 128198 | 70201.2 | 105151.3 |
| Employees Cost | 77613.8 | 72840.4 | 47302.5 | 150597.8 | 141747.3 | 96695.4 |
| Depreciation | 22835.3 | 14820.3 | 15446.9 | 37173.2 | 26761.2 | 28246.9 |
| Other Expenditure | 135145.4 | 103312.9 | 364827.1 | 232243.5 | 191669.2 | 470360.4 |
| Total Expenditure | 452687.9 | 395776.4 | 615502.3 | 735291 | 680977.6 | 898650.6 |
| Total Expenditure | 452687.9 | 14.38 | -26.45 | 735291 | 7.98 | -18.18 |
| Profit from Operations | 114522.3 | 82499.6 | -168287.6 | 160786.1 | 78726 | -156515.1 |
| Profit from Operations | 114522.3 | 38.82 | 168.05 | 160786.1 | 104.24 | 202.73 |
| Other Income | 21963.1 | 27638.7 | 20962.3 | 27948.4 | 29354.5 | 27062.1 |
| Interest | 5419.4 | 3946.6 | 14582.8 | 6138.9 | 7104.3 | 20550.1 |
| Exceptional items | -25458.5 | - | - | -49576.5 | - | - |
| Profit before tax | 156524.5 | 106191.7 | -161908.1 | 232172.1 | 100976.2 | -150003.1 |
| Profit before tax | 156524.5 | 47.4 | 196.67 | 232172.1 | 129.93 | 254.78 |
| Tax Expense | 41651.9 | 48993.3 | -57427.9 | 58487.6 | 69908.7 | -56508.4 |
| Net Profit | 114872.6 | 57198.4 | -104480.2 | 173684.5 | 31067.5 | -93494.7 |
| Net Profit | 114872.6 | 100.83 | -209.95 | 173684.5 | 459.06 | -285.77 |
| Minority Interest | | | | 1255.9 | 1094.5 | 843.7 |
| Share of associates | | | | 591.5 | 323.8 | 782.1 |
| Other Related Items | | | | 22162 | - | - |
| Consolid. Net Profit | | | | 149675.1 | 29649.2 | -95120.5 |
| Consolid. Net Profit | | | | 149675.1 | 404.82 | -257.35 |
| Dividend (%) | 40 | - | - | - | - | - |
| Face Value (in Rs.) | 5 | 5 | 5 | 5 | 5 | 5 |
| Paid-up Equity | 21052 | 21020.9 | 21018.5 | 21052 | 21020.9 | 21018.5 |
| Reserves | 491527.6 | 374854.2 | 333092.2 | 538073.5 | 395023.5 | 391040.3 |
| Basic EPS(in Rs.) | 27.3 | 13.61 | -27.29 | 35.57 | 7.05 | -24.85 |
| Diluted EPS(in Rs.) | 23.75 | 10.74 | -27.29 | 31.48 | 4.6 | -24.85 |
| Public Holding (%) | 34.68 | 34.78 | - | 34.68 | 34.78 | - |
ANNOUNCEMENTS
TO THE NSE
18-03-2011 the Company has fully redeemed US$440,000,000 Zero Coupon Convertible Bonds ("Bonds") on March 18, 2011 (being the maturity date of the Bonds).
01-03-2011 press release dated March 01, 2011, titled "Daiichi Sankyo to Leverage Ranbaxy's Network to Market Its Innovative Products in Singapore".
22-02-2011 press release dated February 22, 2011, titled "RANBAXY FY 2010 PAT AT $327 Mn (Rs. 14968 Mn), UP ON STRONG EARNINGS - Board Recommends Dividend of 40 Percent".
22-02-2011 standalone Results for the year ended on 31-DEC-2010 as follows: Net Sales of Rs. 525148.6 lacs for year ending on 31-DEC-2010 against Rs. 452118 lacs for the year ending on 31-DEC-2009. Net Profit / (Loss) of Rs. 114872.6 lacs for the year ending on 31-DEC-2010 against Rs. 57198.4 lacs for the year ending on 31-DEC-2009.
22-02-2011 consolidated Results for the year ended on 31-DEC-2010 as follows: Net Sales of Rs. 853545 lacs for year ending on 31-DEC-2010 against Rs. 732940.3 lacs for the year ending on 31-DEC-2009. Net Profit / (Loss) of Rs. 149675.1 lacs for the year ending on 31-DEC-2010 against Rs. 29649.2 lacs for the year ending on 31-DEC-2009.
31-01-2011 press release dated January 31, 2011, titled "Ranbaxy and The Government of Yaroslavl Region, Russia, sign MOU for cooperation in the field of Healthcare and Medical Science".
20-12-2010 press release dated December 20, 2010, titled "Sonke, a Black Empowered Pharmaceutical Company, to play significant role in fight against HIV AIDS, in South Africa Wins 21.9% of Government Tender".
30-11-2010 press release dated November 30, 2010, titled "Ranbaxy launches Donepezil 5 MG and 10 MG tablets to U.S. Healthcare System".
01-09-2010 press release dated September 1, 2010, titled ''Ranbaxy sets up new manufacturing facility in South Africa''.
21-07-2010 press release dated July 21, 2010, titled ''Daiichi Sankyo to Leverage Ranbaxy's Network to Market its Innovative Antibiotic Tavanic (Levofloxacin) in Romania and South Africa''.
02-07-2010 press release dated July 02, 2010, titled ''Daiichi Sankyo and Ranbaxy to Integrate New Drug Research and Development System''.
10-06-2010 press release dated June 10, 2010, titled "Ranbaxy Launches Antiplatelet Agent Prasugrel in India".
08-06-2010 Press Release dated June 8, 2010 titled "Ranbaxy launches Generic Atorvastatin, 'Lipogen', a cholestrol-reducing medication in South Africa".
21-05-2010 press release dated May 21, 2010, titled "Ranbaxy launches Atorvastatin, cholesterol-reducing medication into the Canadian Healthcare System".
11-05-2010 press release dated May 11, 2010 , titled "Ranbaxy delivers quarterly sales of over USD 500 MN for the first time, records profit after tax of USD 210 MN".
20-04-2010 "The Company had allotted 23,834,333 Warrants on October 20, 2008 on preferential basis to Daiichi Sankyo Company, Limited (Daiichi Sankyo), each warrant exercisable into one Equity Share at a price of Rs.737 per share at any time between 6 months to 18 months from the date of allotment of warrants and that the Company had received Rs.73.70 per warrant from Daiichi Sankyo, being 10% of the exercise price. In this regard, we wish to inform you that Daiichi Sankyo has not opted to exercise aforesaid warrants into shares. Hence as per the terms of the issue, the said warrants stand lapsed and the amount of Rs.73.70 per warrant aggregating Rs. 1756.59 millions paid by Daiichi Sankyo stand forfeited".
29-03-2010 Press release dated March 29, 2010, titled "Ranbaxy and pfenex Announce Collaboration for the Development of a Biosimilar Therapeutic Protein".
25-02-2010 consolidated Results for the year ended on 31-DEC-2009 as follows: Net Sales of Rs. 732940.3 lacs for year ending on 31-DEC-2009 against Rs. 724140.7 lacs for the year ending on 31-DEC-2008. Net Profit / (Loss) of Rs. 29649.2 lacs for the year ending on 31-DEC-2009 against Rs. (95120.5) lacs for the year ending on 31-DEC-2008.
25-02-2010 standalone Results for the year ended on 31-DEC-2009 as follows: Net Sales of Rs. 452118 lacs for year ending on 31-DEC-2009 against Rs. 430836.2 lacs for the year ending on 31-DEC-2008. Net Profit / (Loss) of Rs. 57198.4 lacs for the year ending on 31-DEC-2009 against Rs. (104480.2) lacs for the year ending on 31-DEC-2008.
* * * E N D * * *
No comments:
Post a Comment